CDK7 and cancer: Previous in vivo studies indicate that global CDK7 loss has minimal impact on non-proliferating tissues while predominantly impacting rapidly dividing cells,22 highlighting CDK7 inhibition as a promising therapeutic strategy for selectively targeting cancer cells with limited toxicity to normal tissues.